Emerging Importance of Tyrosine Kinase Inhibitors against Cancer: Quo Vadis to Cure?
GLOBOCAN 2020 estimated more than 19.3 million new cases, and about 10 million patients were deceased from cancer in 2020. Clinical manifestations showed that several growth factor receptors consisting of transmembrane and cytoplasmic tyrosine kinase (TK) domains play a vital role in cancer progress...
Guardado en:
Autores principales: | Raj Kumar Mongre, Chandra Bhushan Mishra, Arvind Kumar Shukla, Amresh Prakash, Samil Jung, Md Ashraf-Uz-Zaman, Myeong-Sok Lee |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f7e4e2d1c4f14ffe8d65c0a026304786 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer
por: Sareshma Sudhesh Dev, et al.
Publicado: (2021) -
Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?
por: Paula Aldaz, et al.
Publicado: (2021) -
Quo vadis
por: Sienkiwicz, Enrique -
Spleen Tyrosine Kinase Is a Critical Regulator of Neutrophil Responses to <italic toggle="yes">Candida</italic> Species
por: Paige E. Negoro, et al.
Publicado: (2020) -
Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia
por: Yundeok Kim, et al.
Publicado: (2021)